Skip to main content

Table 2 Odds ratios of the risk of stroke in PLWH in Taiwan

From: Herpes zoster associated with stroke incidence in people living with human immunodeficiency virus: a nested case–control study

Variables

Controls

(non-stroke)

(n = 5,090)

Cases (stroke)

(n = 509)

Crude OR

(95% CI)

p-value

Adjusted ORa

(95% CI)

p-value

HZ

 No

4,532 (89.04%)

426 (83.69%)

Reference

 

Reference

 

 Yes

558 (10.96%)

83 (16.31%)

1.58 (1.23–2.03)

 < 0.001

1.85 (1.41–2.41)

 < 0.001

Sex

 Female

419 (8.23%)

46 (9.04%)

Reference

 

Reference

 

 Male

4,671 (91.77%)

463 (90.96%)

0.90 (0.66–1.24)

0.53

0.91 (0.65–1.27)

0.59

Age

 18–34

805 (15.82%)

80 (15.72%)

Reference

 

Reference

 

 35–44

1,591 (31.26%)

159 (31.24%)

1.01 (0.76–1.33)

0.96

0.76 (0.56–1.02)

0.003

 45–54

1,644 (32.29%)

160 (31.43%)

0.98 (0.74–1.30)

0.72

0.54 (0.39–0.73)

0.45

 55–64

787 (15.46%)

84 (16.50%)

1.07 (0.78–1.48)

0.56

0.44 (0.30–0.63)

0.02

  ≥ 65

263 (5.17%)

26 (5.11%)

0.99 (0.63–1.58)

0.93

0.35 (0.21–0.58)

0.007

Geographic area

 North

2,773 (54.48%)

236 (46.37%)

Reference

 

Reference

 

 Central

985 (19.35%)

112 (22.00%)

1.34 (1.05–1.69)

0.04

0.92 (0.81–1.33)

0.24

 South

1,248 (24.52%)

158 (31.04%)

1.49 (1.20–1.84)

0.007

1.24 (0.99–1.55)

0.02

 East

84 (1.65%)

3 (0.59%)

0.46 (0.13–1.34)

0.06

0.38 (0.12–1.30)

0.1

Monthly income, USD

  < 660.50

2,368 (46.52%)

333 (65.42%)

Reference

 

Reference

 

660.50–1321.00

1,840 (36.15%)

148 (29.08%)

0.57 (0.47–0.70)

0.16

0.56 (0.45–0.70)

0.3

  > 1321.04

882 (17.33%)

28 (5.50%)

0.23 (0.15–0.33)

 < 0.001

0.24 (0.16–0.36)

 < 0.001

Comorbidity

 Alcohol-related illness

  No

5,012 (98.47%)

494 (97.05%)

Reference

 

Reference

 

  Yes

78 (1.53%)

15 (2.95%)

1.95 (1.11–3.42)

0.02

1.30 (0.72–2.36)

0.39

 Hypertension

  No

3,752 (73.71%)

236 (46.37%)

Reference

 

Reference

 

  Yes

1,338 (26.29%)

273 (53.63%)

3.24 (2.70–3.90)

 < 0.001

3.53 (2.86–4.34)

 < 0.001

 Diabetes mellitus

  No

4,798 (94.26%)

469 (92.14%)

Reference

 

Reference

 

  Yes

292 (5.74%)

40 (7.86%)

1.40 (0.99–1.98)

0.05

0.72 (0.49–1.08)

0.11

 Hyperlipidemia

 No

3,899 (76.60%)

357 (70.14%)

Reference

 

Reference

 

 Yes

1,191 (23.40%)

152 (29.86%)

1.39 (1.14–1.70)

0.001

1.41 (1.12–1.78)

0.003

 PAOD

  No

5,076 (99.72%)

504 (99.02%)

Reference

 

Reference

 

  Yes

14 (0.28%)

5 (0.98%)

3.60 (1.29–10.04)

0.01

2.61 (0.83–8.17)

0.1

 Coronary artery disease

  No

4,996 (98.15%)

494 (97.05%)

Reference

 

Reference

 

  Yes

94 (1.85%)

15 (2.95%)

1.61 (0.93–2.80)

0.09

1.12 (0.60–2.09)

0.72

 Heart disease

  No

5,626 (97.60%)

468 (91.94%)

Reference

 

Reference

 

  Yes

122 (2.40%)

41 (8.06%)

3.57 (2.47–5.15)

 < 0.001

2.32 (1.54–3.48)

 < 0.001

 Chronic kidney disease

  No

4,957 (97.39%)

476 (93.52%)

Reference

 

Reference

 

  Yes

133 (2.61%)

33 (6.48%)

2.58 (1.75–3.83)

 < 0.001

1.82 (1.16–2.85)

0.01

 HBV

  No

4,193 (82.38%)

409 (80.35%)

Reference

 

Reference

 

  Yes

897 (17.62%)

100 (19.65%)

1.14 (0.91–1.44)

0.26

1.06 (0.83–1.36)

0.63

 HCV

  No

3,493 (68.62%)

279 (54.81%)

Reference

 

Reference

 

  Yes

1,597 (31.38%)

230 (45.19%)

1.80 (1.50–2.17)

 < 0.001

1.49 (1.22–1.83)

 < 0.001

ART regimen

 Only NRTIs

  No

4,212 (82.75%)

421 (82.71%)

Reference

 

Reference

 

  Yes

878 (17.25%)

88 (17.29%)

1.00 (0.79–1.28)

0.98

0.99 (0.74–1.31)

0.93

 Only NNRTIs

  No

4,967 (97.97%)

492 (96.66%)

Reference

 

Reference

 

  Yes

123 (2.03%)

17 (3.34%)

1.40 (0.83–2.34)

0.2

1.25 (0.68–2.29)

0.47

 Only PIs

  No

4,181 (82.14%)

393 (77.21%)

Reference

 

Reference

 

  Yes

889 (17.86%)

116 (22.79)

1.40 (1.12–1.74)

0.003

1.33 (1.05–1.69)

0.02

  1. PLWH People living with HIV, OR Odds ratio, HZ Herpes zoster, USD United States Dollars, PAOD Peripheral arterial occlusive disease, AMI Acute myocardial infarction, HBV Hepatitis B virus, HCV Hepatitis C virus, ART Antiretroviral therapy, NRTIs Nucleoside reverse transcriptase inhibitors, NNRTIs Non-nucleoside reverse transcriptase inhibitors, PIs Protease inhibitors
  2. aOdds ratios were calculated from the logistic regression model adjusted for age, sex, geographic area, monthly income, comorbidity, and ART regimen